The Association and Diagnostic Value Between Maternal Serum Placental Markers and Placenta Previa

Overview

Journal Eur J Obstet Gynecol Reprod Biol X

Specialty Gynecology & Obstetrics

Date 2024 Nov 1

PMID 39483207

Authors

Panpan Ma

Tingting Hu

Yiming Chen

Affiliations

Soon will be listed here.

Abstract

Objective: This study aims to evaluate the correlation and diagnostic value of maternal serum placental markers: pregnancy-associated plasma protein-A (PAPP-A), free beta human chorionic gonadotropin (free β-hCG), and alpha fetoprotein (AFP) in relation to placenta previa.

Methods: A retrospective case-control study was conducted to gather data on 137 pregnant women who were hospitalized for delivery at Hangzhou Women's Hospital. These women participated in the late stage of early and mid-term maternal serum prenatal screening between January 2018 and December 2020. Of the 137 women, 45 were diagnosed with placenta previa, while 92 were selected at random as the control group, in a ratio of 1: 2. Independent samples t-test or Mann-Whitney U test were utilized to compare the quantitative data of the two groups, and the Receiver operating characteristic curve (ROC) was used to evaluate the diagnostic value of maternal serum placental marker levels for placenta previa.

Results: The levels of first trimester and second trimester free beta subunit of human chorionic gonadotropin (FT-Free β-hCG; ST-Free β-hCG) in the placenta previa group were higher than those in the normal group [1.38 (0.55-6.03) MoM vs.1.08 (0.32-4.00) MoM, 1.38 (0.39-4.10) MoM vs.1.01 (0.29-4.12) MoM], and the differences between the groups were statistically significant ( = 2.830, = 2.846, both < 0.05). The AFP level was higher than the normal group [1.13 (0.65-2.15) MoM vs. 0.94 (0.51-2.02) MoM], and the difference was statistically significant ( = 2.551, < 0.05). There was no significant difference in PAPP-A between the placenta previa group and the normal group ( = 1.396, > 0.05). The ROC curve analysis results showed that the AUCs of FT-Free β-hCG and ST-Free β-hCG for placenta previa were 0.649 (95 % CI: 0.551-0.747, = 0.005), 0.634 (95 % CI: 0.539-0.730, = 0.011), and 0.650 (95 % CI: 0.554-0.746, P = 0.004). Using PPV, NPV, FPR, FNR, +LR, and -LR as evaluation indicators for the 5 models, the results showed that FT-Free β-hCG was the best performer in terms of PPV, FPR, and +LR, with values of 0.725, 0.600, and 2.632, respectively. The three-indicator combined detection model (AFP + ST-Free β-hCG + FT-Free β-hCG) had the best performance in terms of NPV and -LR, with values of 0.770 and 0.298, respectively.

Conclusion: The elevated maternal serum levels of Free β-hCG and AFP may be associated with placenta previa. The combined detection of maternal serum markers in the early and mid-trimesters has better diagnostic value for predicting placenta previa than individual detection.

References

Berezowsky A, Pardo J, Ben-Zion M, Wiznitzer A, Aviram A . Second Trimester Biochemical Markers as Possible Predictors of Pathological Placentation: A Retrospective Case-Control Study. Fetal Diagn Ther. 2019; 46(3):187-192. DOI: 10.1159/000492829. View

Honarjoo M, Zarean E, Tarrahi M, Kohan S . Role of pregnancy-associated plasma protein A (PAPP-A) and human-derived chorionic gonadotrophic hormone (free β-hCG) serum levels as a marker in predicting of Small for gestational age (SGA): A cohort study. J Res Med Sci. 2022; 26:104. PMC: 8765518. DOI: 10.4103/jrms.JRMS_560_20. View

Wang Y, Hu C, Pan N, Chen C, Wu R . Prophylactic uterine artery embolization in second-trimester pregnancy termination with complete placenta previa. J Int Med Res. 2018; 47(1):345-352. PMC: 6384468. DOI: 10.1177/0300060518801455. View

Cai S, Wu Y, Zeng L, Ding Y . Value of 3D ultrasound flow imaging combined with serum AFP, β-hCG, sFlt-1 and CK in the diagnosis of placenta accreta. BMC Womens Health. 2022; 22(1):556. PMC: 9798680. DOI: 10.1186/s12905-022-02107-z. View

Chen Y, Xie Z, Wang X, Xiao Q, Lu X, Lu S . A risk model of prenatal screening markers in first trimester for predicting hypertensive disorders of pregnancy. EPMA J. 2020; 11(3):343-353. PMC: 7429630. DOI: 10.1007/s13167-020-00212-3. View

Sovio U, Gaccioli F, Cook E, Charnock-Jones D, Smith G . Association between adverse pregnancy outcome and placental biomarkers in the first trimester: A prospective cohort study. BJOG. 2023; 131(6):823-831. DOI: 10.1111/1471-0528.17691. View

Dai X, Zhang H, Wu B, Ning W, Chen Y, Chen Y . Correlation between elevated maternal serum alpha-fetoprotein and ischemic placental disease: a retrospective cohort study. Clin Exp Hypertens. 2023; 45(1):2175848. DOI: 10.1080/10641963.2023.2175848. View

. Correction to: Farzad Mohajeri et. al., Ultrasound measurement of fetal adrenal gland in fetuses with intrauterine growth restriction, an early predictive method for adverse outcomes. J Matern Fetal Neonatal Med. 2017; 32(18):3136. DOI: 10.1080/14767058.2017.1419797. View

Mobed A, Abdi B, Masoumi S, Mikaeili M, Shaterian E, Shaterian H . Advances in human reproductive biomarkers. Clin Chim Acta. 2023; 552:117668. DOI: 10.1016/j.cca.2023.117668. View

10.

Skogler J, Moberg T, Tancredi L, Styrmisdottir L, Hedayati E, Alarcon-Ruiz C . Association between human chorionic gonadotropin (hCG) levels and adverse pregnancy outcomes: A systematic review and meta-analysis. Pregnancy Hypertens. 2023; 34:124-137. DOI: 10.1016/j.preghy.2023.11.003. View

11.

Borovkov V, Igitova M, Korenovskiy Y, Dudareva Y . [Prognostic significance of specific proteins of pregnancy in women with a uterine scar and placenta accreta.]. Klin Lab Diagn. 2020; 65(6):353-357. DOI: 10.18821/0869-2084-2020-65-6-353-357. View

12.

Turner J, Kumar S . Low First Trimester Pregnancy-Associated Plasma Protein-A Levels Are Not Associated with an Increased Risk of Intrapartum Fetal Compromise or Adverse Neonatal Outcomes: A Retrospective Cohort Study. J Clin Med. 2020; 9(4). PMC: 7230680. DOI: 10.3390/jcm9041108. View

13.

Chen Y, Wang X, Chen Y, Ning W, Chen L, Yin Y . Construction and predictive value of risk models of maternal serum alpha-fetoprotein variants and fetal open neural tube defects. Exp Biol Med (Maywood). 2022; 247(10):822-831. PMC: 9160932. DOI: 10.1177/15353702221080458. View

14.

Cui R, Li M, Lu J, Bai H, Zhang Z . Management strategies for patients with placenta accreta spectrum disorders who underwent pregnancy termination in the second trimester: a retrospective study. BMC Pregnancy Childbirth. 2018; 18(1):298. PMC: 6042202. DOI: 10.1186/s12884-018-1935-6. View

15.

Zhang L, Wang W, Hou Y . Analysis of the Risk Factors for Massive Hemorrhage in Pernicious Placenta Previa and Evaluation of the Efficacy of Internal Iliac Artery Balloon Occlusion. Int J Womens Health. 2022; 14:1769-1776. PMC: 9790154. DOI: 10.2147/IJWH.S379965. View

16.

Guo X, Wang F, Li J, Guo Z, Wang J . Prediction performance of serum placental growth factor (PLGF) human chorionic gonadotropin β (β-hCG) and PAPP-A levels in early pregnancy for pregnancy outcomes. Pak J Med Sci. 2022; 38(7):1877-1882. PMC: 9532635. DOI: 10.12669/pjms.38.7.5248. View

17.

Zhao H, Wang Q, Han M, Xiao X . Current state of interventional procedures to treat pernicious placenta previa accompanied by placenta accreta spectrum: A review. Medicine (Baltimore). 2023; 102(37):e34770. PMC: 10508584. DOI: 10.1097/MD.0000000000034770. View

18.

Aryananda R, Duvekot J, van Beekhuizen H, Cininta N, Ariani G, Dachlan E . Transabdominal and transvaginal ultrasound findings help to guide the clinical management of placenta accreta spectrum cases. Acta Obstet Gynecol Scand. 2023; 103(1):93-102. PMC: 10755131. DOI: 10.1111/aogs.14715. View

19.

Jauniaux E, Dimitrova I, Kenyon N, Mhallem M, Kametas N, Zosmer N . Impact of placenta previa with placenta accreta spectrum disorder on fetal growth. Ultrasound Obstet Gynecol. 2019; 54(5):643-649. PMC: 6699933. DOI: 10.1002/uog.20244. View

20.

Buke B, Akkaya H, Demir S, Sagol S, Simsek D, Basol G . Relationship between first trimester aneuploidy screening test serum analytes and placenta accreta. J Matern Fetal Neonatal Med. 2016; 31(1):59-62. DOI: 10.1080/14767058.2016.1275546. View